drugset / Trial / NCT05485155
Zemaira Eosinophilic Esophagitis Pilot Study
Phase 2
Recruiting
15 enrolled
Children's Hospital Medical Center, Cincinnati
CSL Behring · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.
Timeline
- Start
- 2025-05-15
- Primary completion
- 2026-10
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpha 1-Antitrypsin | Protein / enzyme biologic | 120 mg/kg | Intravenous |